Noninvasive Drug-delivery Technology for Ocular Use
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments. OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES. OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.